Caprine herpesvirus type 1 (CpHV-1)
39944
Caprine herpesvirus type 1 (CpHV-1) is an alphaherpesvirus causing genital disease leading to abortion in adult pregnant goats and a systemic disease with high morbility and mortality in kids. CpHV-1 infection also represents a valuable large animal model for human herpesvirus induced genital disease, exploitable for pathogenic studies, new vaccines and antiviral molecules testing (Donofrio et al., 2013).
Baboon
Papio cynocephalus
9556
Bank vole
Clethrionomys glareolus
447135
Bear
Ursus americanus
9643
Birds
Passeroidea
175121
Brown Trout
Salmo trutta
8032
Buffalo
Bison bison
9901
Carnivores
Vulpes
9625
Cat
Felis catus
9685
Catfishes
Siluriformes
7995
Cattle
Bos taurus
9913
Chicken
Gallus gallus
9031
Chimpanzee
Pan troglodytes
9598
chinchillas
Chinchillidae
10150
Copper Pheasant
Syrmaticus soemmerringii
9067
Deer
Cervus elaphus
9860
Deer mouse
Peromyscus maniculatus
10042
Dog
Canis familiaris
9615
Ducks
Anas
8835
Ferret
Mustela putorius furo
9669
Fish
Hyperotreti
117565
Gerbil
Gerbillina
10045
Goat
Capra hircus
9925
Gray wolf
Canis lupus
9612
Guinea pig
Cavia porcellus
10141
Hamster
Mesocricetus auratus
10036
Horse
Equus caballus
9796
Human
Homo sapiens
9606
Macaque
Macaca fascicularis
9541
Mongolian Gerbil
Meriones unguiculatus
10047
Monkey
Platyrrhini
9479
Mouse
Mus musculus
10090
None
None
Parrot
Psittacidae
9224
Pig
Sus scrofa
9823
Rabbit
Oryctolagus cuniculus
9986
Rainbow trout
Oncorhynchus mykiss
8022
Rat
Rattus
10114
Raven
Corvus corax
56781
sei whale
Balaenoptera borealis
9768
Sheep
Ovis aries
9940
Squirrel
Spermophilus richardsonii
37591
Tree shrew
Tupaiidae
9393
Trouts, salmons & chars
Salmoninae
504568
Turkey
Meleagris gallopavo
9103
Vole
Microtus ochrogaster
79684
Water buffalo
Bubalus bubalis
391902
BoHV-4-A-gD(cp)gD(106)ΔTK
VO_0004685
Recombinant vector vaccine
Research
Intramuscular injection (i.m.)
The bovine herpesvirus 4 (BoHV-4) based vector derived from an apathogenic isolate of BoHV-4 was used to express the immunodominant CpHV-1 glycoprotein D (BoHV-4-A-gD(cp)gD(106)ΔTK) (Donofrio et al., 2013).
Intramuscular injection (i.m.)
No clinical signs were evident but a good titer of serum neutralizing antibodies was produced in all inoculated animals (Donofrio et al., 2013).
Goats were vaccinated with BoHV-4-A-gD(cp)gD(106)ΔTK (Donofrio et al., 2013).
VO_0003057
All the vaccinated goats with BoHV-4-A-gD(cp)gD(106)ΔTK were protected toward CpHV-1 induced genital disease respect to the unvaccinated control goat who showed typical vaginal lesions with a high grade of clinical score as well as a long lasting viral shedding (Donofrio et al., 2013).
A challenge experiment was performed in a new group of animals using a highly pathogenic dose of CpHV-1 (Donofrio et al., 2013).
CpHV-1 Vaccine MF59 Adjuvant
Inactivated or "killed" vaccine
Research
subcutaneous injection
inactivated CpHV-1 plus MF59™ as adjuvant was strongly immunogenic and induced effective immunity against vaginal CpHV-1 infection in goats. (Marinaro et al., 2012)
oil-in-water emulsion MF59 (Novartis Vaccines and Diagnostics, Siena, Italy) (Marinaro et al., 2012)
subcutaneous injection
CpHV-1 (Marinaro et al., 2012)
Detection and quantitation of latent CpHV-1 DNA in sacral ganglia in challenged goats revealed that the inactivated CpHV-1 plus MF59™ vaccine was able to significantly reduce the latent viral load when compared either to the naïve goats or to the goats vaccinated with inactivated CpHV-1 in the absence of adjuvant. (Marinaro et al., 2012)
The twenty-eight goats received either 2 ml of inactivated CpHV-1 (10^6.5 TCID50/50 µl) plus 2 ml of sterile saline solution or received 2 ml of inactivated CpHV-1 emulsified with 2 ml of MF59™ or were left unvaccinated (these animals served as naïve controls in challenge studies). After preparation, vaccines were immediately injected subcutaneously in the neck. All goats were vaccinated with two doses of vaccine (one dose on day 0 and one dose on day 10). (Marinaro et al., 2012)
Vaginal disease was not detected in goats vaccinated with inactivated CpHV-1 plus MF59™ and these animals had undetectable levels of infectious challenge virus in their vaginal washes. Goats vaccinated with inactivated CpHV-1 in the absence of adjuvant exhibited a less severe disease when compared to naïve goats but shed titers of challenge virus that were similar to those of naïve goats. (Marinaro et al., 2012)
No systemic adverse reactions were observed in any goat included in the study. (Marinaro et al., 2012)
The vaginal challenge was performed by pipetting four milliliters of virulent CpHV-1 suspension (10^5 TCID50/50 µl) into the vaginal lumen of naïve animals or vaccinated animals (Marinaro et al., 2012).
Donofrio et al., 2013
journal
Donofrio G, Franceschi V, Lovero A, Capocefalo A, Camero M, Losurdo M, Cavirani S, Marinaro M, Grandolfo E, Buonavoglia C, Tempesta M
Clinical protection of goats against CpHV-1 induced genital disease with a BoHV-4-based vector expressing CpHV-1 gD
2013
8
1
e52758
PloS one